Trial · NCT05708274
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
NCT05708274, Phase 1, Completed, Bronx VA Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacological Agents for Chronic Spinal Cord Injury (SCI). Trials, record NCT05708274. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05708274
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
- NCT number
- NCT05708274
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 25 participants, actual
- Lead sponsor
- Bronx VA Medical Center
- Conditions
- Spinal Cord Injuries
- Interventions
- CPH + hand training, CD-LD + hand training, ATX + hand training, Placebo + hand training
- First posted
- 2023-02-01
- Last updated
- 2025-12-08
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessing task performance (dexterity) | Assess change from baseline to 10 minutes after completion of drug+task training. | Unilateral manual dexterity will be assessed using the 9-Hole Peg Test (Aim 1a). |
| Secondary | Assessing task performance (dexterity) | Assess change from baseline to 10 minutes after completion of drug+task training. | Unilateral manual dexterity will be assessed using the Box and Block Test (Aim 1a). |
| Secondary | Assessing volitional grip strength | Assess change from baseline to 10 minutes after completion of drug+task training. | Maximal grip force will be measured (Aim 1b). The attempt with the highest value will be used for analysis. |
| Secondary | Assessing volitional pinch strength | Assess change from baseline to 10 minutes after completion of drug+task training. | Maximal pinch force will be measured (Aim 1b). The attempt with the highest value will be used for analysis. |
| Secondary | Assessing corticospinal plasticity | Assess change from baseline to 10 minutes after completion of drug+task training. | Corticospinal plasticity will be measured via single-pulse TMS recruitment curves (Aim 2a). |
| Secondary | Assessing cortical plasticity | Assess change from baseline to 10 minutes after completion of drug+task training. | Short intracortical inhibition (SICI) and intracortical facilitation (ICF) will be evoked with paired-pulse TMS at various interstimulus intervals according to the methods previously employed (Murray \& Knikou, 2017). |
| Secondary | Assessing spinal plasticity | Assess change from baseline to 10 minutes after completion of drug+task training. | Spinal plasticity will be measured via single-pulse TSCS recruitment curves (Aim 2b). |
| Secondary | Tracking cardiovascular responses (heart rate) | Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline. | Observed measures of heart rate (HR) (Aim 3a) will be monitored throughout. |
| Secondary | Tracking cardiovascular responses (blood oxygen saturation) | Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline. | Observed measures of blood oxygen saturation (SpO2) (Aim 3a) will be monitored throughout. |
| Secondary | Tracking cardiovascular responses (blood pressure) | Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline. | Observed measures of blood pressure (BP) (Aim 3a) will be monitored throughout. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05708274
GET https://conductscience.org/api/trials/v1/NCT05708274/registered